Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-01-29 08:51 am Sale | 13G | Zyla Life Sciences ZCOR | Tekla Capital Management LLC | 0 0.000% | -656,921 (Position Closed) | View |
| 2020-05-22 4:07 pm Sale | 13D | Zyla Life Sciences ZCOR | CR Group L.P. | 0 0.000% | -7,023,333 (Position Closed) | View |
| 2020-03-26 4:26 pm Purchase | 13D | Zyla Life Sciences ZCOR | DEPOMED INC DEPO | 4,854,863 51.000% | 4,854,863 (New Position) | View |
| 2020-03-25 8:53 pm Unchanged | 13D | Zyla Life Sciences ZCOR | CR Group L.P. | 7,023,333 58.700% | 0 (Unchanged) | View |
| 2020-02-13 5:28 pm Unchanged | 13G | Zyla Life Sciences ZCOR | Broadfin Capital LLC | 0 0.000% | 0 (Unchanged) | View |
| 2020-02-13 5:25 pm Purchase | 13G | Zyla Life Sciences ZCOR | CI INVESTMENTS INC. | 935,161 9.990% | 935,161 (New Position) | View |
| 2020-02-13 4:23 pm Purchase | 13G | Zyla Life Sciences ZCOR | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,260,624 9.990% | 2,260,624 (New Position) | View |
| 2020-02-12 5:15 pm Sale | 13G | Zyla Life Sciences ZCOR | Riva Ridge Capital Management LP | 938,661 10.000% | -300,000 (-24.22%) | View |
| 2020-01-24 08:03 am Purchase | 13G | Zyla Life Sciences ZCOR | Tekla Capital Management LLC | 656,921 7.000% | 656,921 (New Position) | View |